Identifies desethylamiodarone as the major lipophilic metabolite of amiodarone in human plasma, present at concentrations comparable to the parent drug.
Answers are grounded in this paper and cite their sources.
Desethylamiodarone levels may inform amiodarone monitoring; leaves open its contribution to efficacy and toxicity.
Desethylamiodarone has been identified as the principal lipophilic metabolite of amiodarone present in plasma specimens from amiodarone-treated patients. This structure has been confirmed by probe-injection mass spectrometry of column effluent fractions and comparison with the authentic compound using both chromatographic and mass spectrometric techniques. Although there is no information available as to the pharmacological activity of desethylamiodarone in man, the plasma concentrations of this metabolite attained during chronic amiodarone therapy are similar to those of the parent compound (0.1-4 mg litre-1).
No takes yet. Share an insight, caveat, or question.
Flanagan et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: